A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAHS Cancer Control Alberta
About this trial
This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.
Eligibility criteria
Qualifiers
Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma,
Stable clinical status as deemed by responsible investigator,
Personally (or caregiver) willing and deemed capable to self-administer with teaching,
Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment,
Disqualifiers
Currently participating in clinical trials that includes the use of bortezomib,
History of allergic reactions to bortezomib,
History of bleeding attributable to bortezomib,
History of greater than or equal to grade 3 side effects attributable to bortezomib,
Trial design
Treatments tested in this trial
- Bortezomib Injection
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov